Scientific milestones achieved significantly ahead of schedule Cambridge, UK, 19 January 2023 – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces the completion of its £21.5m (US $28.5m) Series B financing, with a £6m (US $7.5m) financing extension. The syndicate comprised its Series B subscribing investors including CRT Pioneer Fund, Claris Ventures, 2Invest, […]
Deal value of up to US$525 million Novo Holdings co-led ReViral Series B financing in 2018 ReViral developing novel antiviral therapies to treat RSV infections Validation of Novo Holdings’ strategy to identify and invest in high quality European biotech opportunities Copenhagen, Denmark – Novo Holdings A/S, a leading international life sciences investor, today announces that its […]
Precirix NV, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology, today announces the closing of a EUR 80m Series B financing round led by new investors INKEF Capital, Jeito Capital and Forbion as co-leads. Read more
Read more on VelosBio in this latest blog post by Arix Managing Director and VelosBio Board Director Jonathan Tobin
Syncona leads £32.0 million Series B financing of Azeria Therapeutics with a £29.5 million commitment Opportunity to address a significant unmet need in oestrogen receptor positive breast cancer patients in lead programme and to build a world class pioneer factor oncology company London, 21 November 2019 – Azeria Therapeutics (Azeria), a newly formed pioneer factor […]